Isitri (Isosorbide Dinitrate)

Isosorbide dinitrate is converted in the body to nitric oxide, which activates guanylate cyclase in vascular smooth muscle. The resulting rise in cyclic GMP causes relaxation of both arterial and venous vessels, lowering preload and afterload and decreasing myocardial oxygen demand.

The dose of Isitri is individualized by the prescribing clinician based on the patient’s clinical condition, route of administration (intravenous or intracoronary), and response to therapy. Healthcare professionals determine the appropriate strength, infusion rate, and frequency according to established guidelines and patient tolerance.

Safety data for isosorbide dinitrate in pregnancy and lactation are limited. The product should only be used when the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To order Isitri, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Isitri (isosorbide dinitrate) belongs to the organic nitrate class, offering rapid vasodilation via nitric oxide release. Compared with short‑acting nitroglycerin, it has a longer duration of action and more predictable plasma levels when given intravenously. Unlike beta‑blockers, it does not reduce heart rate directly but primarily lowers preload and afterload.

Store Isitri at room temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and avoid freezing. Ensure that the solution is used before the expiration date and that any reconstituted product follows the manufacturer’s stability guidelines.

Isitri is supplied as an injectable solution for use by qualified healthcare professionals. It can be administered intravenously as a continuous infusion or bolus, or delivered intracoronarily during cardiac procedures. Administration techniques, infusion rates, and monitoring protocols are determined by the treating physician based on the clinical scenario.

The most serious risks include severe hypotension that can lead to syncope, myocardial infarction triggered by abrupt blood pressure drops, life‑threatening allergic reactions, and rare cases of methemoglobinemia. Patients should be closely monitored for signs of these events, especially during initial dosing or when combined with other vasodilators.

Isitri is contraindicated in patients with severe hypotension, recent use of phosphodiesterase‑5 inhibitors, known hypersensitivity to organic nitrates, or those with certain forms of cardiogenic shock. Caution is also advised for individuals with significant anemia, recent myocardial infarction, or uncontrolled heart failure until stability is achieved.